1 and drives CD4 decline independently of the viral load.
2 gical sequelae at 6 months of age, or plasma viral load.
3 enes and gene sets for an influence on HIV-1 viral load.
4 ntiviral interferon expression and decreased viral load.
5 at any time during hospitalization, and high viral load.
6 ght loss, airway inflammation, and pulmonary viral load.
7 after RSV infection associated with reduced viral load.
8 with antiretroviral exposure and low plasma viral load.
9 HCV infection was defined by detectable HCV viral load.
10 on HBsAg testing and had an undetectable HBV viral load.
11 redictors of patient outcome, independent of viral load.
12 motor impairment, mortality, and spinal cord viral load.
13 group, calendar year, cohort, CD4 count, and viral load.
14 over time and correlated with the individual viral load.
15 f infected cells in the intestine and plasma viral load.
16 spiratory symptoms, lung function, and nasal viral load.
17 wed a significant, positive correlation with viral load.
18 s in infected mice and decreased spinal cord viral loads.
19 pairment, increased mortality, and increased viral loads.
20 iruses by lessening weight loss and lowering viral loads.
21 oxetine had no effect on motor impairment or viral loads.
22 (>50,000) or low (<10,000 HIV RNA copies/ml) viral loads.
23 th CD4 T cell counts and positively with HIV viral loads.
24 ive antiretroviral therapy with undetectable viral loads.
25 and HPS/CTM v2 in samples with quantifiable viral loads.
26 utations showed no significant difference in viral loads.
27 r BA, infants with GA5 infections had higher viral loads.
28 atients with CMV pneumonia had higher median viral loads (3.9 log10 IU/mL; interquartile range [IQR],
29 as 37 years, CD4 count 321 cells/microL, and viral load 4.5 log10 copies/mL.
30 At baseline, 9 patients had a detectable HBV viral load, 7 had positive results on hepatitis B surfac
31 ptoms, with the IgM decrease paralleling the viral load after graft removal.
32 In subjects who achieved undetectable viral load after treatment (n = 33), a higher baseline t
33 nical virology, and accurate quantitation of viral load among labs requires the use of international
34 Although we found higher viral loads among pneumonia cases than controls for some
35 ART, as reflected by a rapid drop in plasma viral load and a dramatic decrease in the levels of cell
36 disease severity and viral load (P = .994); viral load and adverse outcomes (P = .667; OR: 1.02; 95%
37 e breastfeeding; ART treatments can suppress viral load and are key to preventing transmission to the
38 Treg cells was analyzed and correlated with viral load and CD4(+) T-cell counts/percentages in 93 HI
39 Associations between viral load and demographic, obstetrical, HCV risk factor
40 In summary, we conclude that the viral load and EBV gp350 diversity during early infectio
41 oversial without considering the role of HCV viral load and genotype.
42 prick blood samples, the Cepheid Xpert HIV-1 Viral Load and HIV-1 Qual cartridges were compared with
43 ody levels, ASCs and HAI titers with reduced viral load and inflammatory responses in the cVLP group.
44 ans was correlated positively with set-point viral load and negatively with duration of viral suppres
45 Importantly, it reveals that initial high viral load and neutralizing IgG response may function in
46 approved medications can reliably reduce the viral load and prevent the progression of liver diseases
47 lpha (IL-27RA) axis as a predictor of plasma viral load and proviral copy number in the peripheral bl
48 immune response and as robust correlates of viral load and proviral reservoir size in PBMC.IMPORTANC
49 conclusion, the correlation between patient viral load and replication kinetics of RSV patient isola
50 omatic cases in the relationship between the viral load and the response kinetics, emphasizing how mu
51 Interestingly, viral load and tissue viremia, but not intermittent vira
52 ness in which patients have high circulating viral loads and an exaggerated virus-induced immune resp
53 ssignment was stratified by plasma HIV-1 RNA viral loads and CD4 cell count at baseline.
54 We measured viral loads and cytokine profile during patients' acute
55 ce the nucleoside analogue entecavir reduced viral loads and decreased liver inflammation.
56 um is especially susceptible, harboring high viral loads and displaying marked neuropathology, with m
57 ETH users have been shown to have higher HIV viral loads and experience more severe neurological comp
58 V/AIDS slows disease progression by reducing viral loads and increasing CD4 counts.
59 Including 140 subjects with variable viral loads and measuring the plasma levels of >600 solu
60 -deficient mice had significantly higher CNS viral loads and mortality rates than wild-type animals.
61 yte (Hu-PBL)] mice by completely suppressing viral loads and preventing human CD4(+) T-cell loss.
62 s (HIV or SIV), respectively, express higher viral loads and progress more rapidly to AIDS than infec
63 graft removal, which led to decreasing serum viral loads and resolution of neurological symptoms.
64 of clinical signs for 2 years, despite high viral loads and the accumulation of large intracellular
65 DENV2 infection on the basis of undetectable viral loads and the lack of an anamnestic antibody respo
66 (HBsAg) testing and had an undetectable HBV viral load, and 3 had negative results on HBsAg testing
67 eloped more-severe immunosuppression, higher viral load, and a broader range of clinical signs typica
68 ltivariable analysis, age, historical plasma viral load, and ART regimen changes prior to interruptio
69 eristics, neuroimaging abnormalities, plasma viral load, and audiological and neurological outcomes o
70 Viral serology, viral load, and liver biochemistry were performed at reg
71 ed in enhanced innate immunity, a diminished viral load, and morbidity in vivo.
72 60 after adjusting for age, tobacco smoking, viral load, and traditional risk factors (odds ratio [OR
73 tegrated next generation sequencing, patient viral load, and viral replication analysis with surveill
74 the blood-brain barrier (BBB), higher brain viral loads, and higher brain inflammatory cytokine and
75 lerated viral suppression, further decreased viral loads, and reduced the persistently infected HIV r
76 r conditions where other predictors, such as viral load, are poor prognostic indicators.
77 osure on the basis of the maximum cumulative viral load area under the curve (AUC) (P = .054).
78 tick collection with the Abbott RealTime HCV Viral Load assay (gold standard).
79 Sensitivity of the Xpert HCV Viral Load assay for HCV RNA detection in plasma collect
80 Sensitivity of the Xpert HCV Viral Load assay for HCV RNA detection in samples collec
81 in serum and plasma by the Cepheid Xpert HCV Viral Load assay in comparison to the Abbott RealTime HC
82 The Xpert HCV Viral Load assay performs well compared to a market-lead
83 rnal quality assessment panel, the Xpert HCV Viral Load assay results (quantified in log10 IU per mil
84 e evaluated the performance of the Xpert HCV Viral Load assay with venepuncture and finger-stick capi
85 These were tested with the Xpert HCV Viral Load assay, and results were compared to quantific
86 ed virologic response as defined as negative viral load at 12 weeks postcompletion of therapy and all
87 and estimated the heritability of set-point viral load at 31% (CI 15%-43%).
88 Humoral immunity was associated with viral load at presentation: 40 of 43 patients (93.0%) wi
89 the treated patients, 100% had undetectable viral load at the completion of therapy.
90 elease, and 301 (29%) of 1042 had detectable viral loads at LTC.
91 the fraction of variation in HIV-1 set point viral load attributable to viral or human genetic factor
92 The maximum cumulative viral load AUC was the best predictor of early (days 0-1
93 were significantly higher in patients with a viral load below 800 000 (100% vs 83.9%, P value = 0.022
94 ples versus 13 of 68 (19.1%) patients with a viral load below this level (P < .001).
95 Following peak viral loads, both participants experienced full suppress
96 ciency virus (SHIV), we observe a lower peak viral load but an unchanged viral set point during viral
97 d the EVGcobi groups reached an undetectable viral load but only 58.3% in the DRVrtv arm (P = .003).
98 associated with mean CD4 cell counts or HIV viral load but was associated with younger maternal age
99 ior to ART did not correlate with HIV plasma viral load, but positively associated with plasma sCD14
100 % of those on treatment to have a suppressed viral load by 2020, with each individual target reaching
101 lethal disease and reduced serum and tissue viral loads by 3 to 6 orders of magnitude.
102 with a lethal dose of Ebola virus suppressed viral loads by more than 5 logs and protected animals fr
103 use showed no significant associations with viral load, CD4 counts, AIDS, cancer, or mortality in bo
104 Traditional cardiovascular risk factors, HIV viral load, CD4 lymphocyte count, statin use, antihypert
105 te with HIV disease progression, measured by viral load, CD4 percentage, CD4:CD8 T-cell ratio, and im
106 ated with markers of viral disease activity (viral load, CD8+ T cells, and CD4/CD8 ratio) and CD4+ T-
107 ment effects on the primary outcome of log10 viral load collected at months 5, 10, and 15.
108 a higher rebound set point but similar peak viral loads compared to the primary infection.
109 ficient for the virus to evolve intermediate viral loads consistent with maximising transmission, as
110 To determine if viral load could provide evidence of causality of pneumo
111 ROC curves to determine the optimal viral load cutoff produced an area under the curve of <0
112 structed to determine optimal discriminatory viral load cutoffs.
113 Viral load density distributions were plotted.
114 Viral load did not impact SVR rates in cohort B.
115 However, there was substantial overlap in viral load distribution of cases and controls for all vi
116 ammation whose expression is associated with viral load during experimental rhinovirus infection of a
117 g revealed that patients with higher initial viral loads during the acute phase of illness had poor p
118 d used to measure CD4 cell count and HIV RNA viral load every 3-6 months (when below the threshold) o
119 models of character evolution describing how viral load evolves on the phylogeny of whole-genome vira
120 research showing the benefits of suppressed viral load for the individual and the whole population.
121 Samples with HIV RNA viral load greater than 1000 copies per mL were selected
122 ith a lenient threshold of viraemia (HIV RNA viral load >/=1000 copies per mL).
123 icipants with virological rebound (confirmed viral load >/=50 copies per mL or premature discontinuat
124 mL or premature discontinuations, with last viral load >/=50 copies per mL) cumulative through week
125 esentation: 40 of 43 patients (93.0%) with a viral load >/=7.0 log10 copies/mL serum developed the ex
126 VF was defined by a plasma viral load >1000 copies/mL >/=6 months after initiating
127 ernal hepatitis B e-antigen (HBeAg) and high viral load have been noted to be the most important risk
128 High viral load, high-dose steroids, and myeloablative condit
129 ablated interferon production and increased viral load; however, the heightened immunopathology and
130 can predict CD4 decline independently of the viral load (HR = 2.9; P = 0.004) or protective HLA allel
131 Initial viral load, IgG, and initial neutralization response wer
132 eck") that includes stabilising selection on viral load; (iii) we controlled for covariates, includin
133 Of these, we measured viral load in 8828 (73.8%) people.
134 tent reservoir size and the relationships to viral load in acute HIV infection, measurements of the l
135 Despite comparable levels of viral load in circulating blood cells and peripheral org
136 nt with other studies based on regression of viral load in donor-recipient pairs.
137 Interestingly, the viral load in salivary glands and oral lavage was strong
138 We measured viral load in stored samples for all patients obtained e
139 related to an increase in RABV mRNA and live viral load in the brain, as well as to an accelerated sp
140 numbers were positively correlated with CMV viral load in the dried blood spots.
141 fp683-dependent liver ILC1 lead to increased viral load in the presence of intact adaptive and innate
142 dence of causality of pneumonia, we compared viral load in the URT of children with World Health Orga
143 t was low, despite a significantly lower HIV viral load in those recently started on treatment (P < .
144 A single dose of N6-LS suppressed plasma viral loads in 4 out of 5 animals at day 7, while the co
145 , adjuvanted G protein significantly reduced viral loads in both the lungs and nose at early time poi
146 ness of fit test based on the correlation of viral loads in cherries of the phylogenetic tree, showin
147 ted the role of RSV subtypes, genotypes, and viral loads in disease severity and host transcriptional
148 Patients with higher peripheral blood viral loads in primary infection and greater changes in
149 osquito bite delays ZIKV replication to peak viral loads in rhesus macaques.
150 ased morbidity-including fever, viremia, and viral loads in spinal cord and testes-and increased mort
151 ntil several months later, by which time the viral loads in the blood had already fallen.
152 hat in five cases of asymptomatic infection, viral loads in the blood were as high as those in patien
153 strate that N6-LS potently suppressed plasma viral loads in the majority of animals but that the comb
154 es concurrently in 11 patients, with average viral loads in urine a log higher than those in serum.
155 Interestingly, in another case with a higher viral load, in which T and NK cell responses were undete
156 not detected in pretransplant serum, however viral loads increased with time, peaking during the heig
157 In this study, AIMS reduced viral load, increased QALYs, and saved resources.
158 Persistent high EBV viral load is associated with the occurrence of solid ca
159 ciated neurological disorders, even when the viral load is low.
160 Inoculation with different viral loads led to different immune responses and levels
161 positive and HIV negative) with a detectable viral load (local prevalence of viraemia).
162 to be receiving effective antiviral therapy (viral load <100 IU/mL); antiviral therapy was not requir
163 redicted-active NRTIs had viral suppression (viral load <400 copies per mL) at week 144, compared wit
164 nt-experienced and virologically suppressed (viral load <50 copies per mL for >/=2 months; one viral
165 not have cirrhosis, and have a pretreatment viral load <6,000,000 IU/mL.
166 se combinations is largely disconnected from viral loads measured during treatment.
167 We examined time to LTC (defined as first viral load measurement after release) and viral suppress
168 WHO-defined virological failure (one or more viral load measurement of >/=1000 copies per mL) and swi
169 as defined as the occurrence of at least one viral load measurement of 51-999 copies per mL during AR
170 We sought to measure population viral load metrics to assess viral suppression and chara
171 Effective viral load monitoring and point-of-care resistance tests
172 ere therapeutic drug monitoring and/or close viral load monitoring are feasible to detect suboptimal
173 Viral load monitoring for hepatitis C virus (HCV) is nec
174 Landon Myer and colleagues discuss viral load monitoring for pregnant HIV-positive women an
175 pact of HIVDR: (1) routine access to routine viral load monitoring in all settings; (2) optimization
176 half of failures, highlighting the value of viral load monitoring of second-line ART.
177 ange, 2.8-16.8 months) in this setting where viral load monitoring was available.
178 agnosis of HIV from dried blood spots (DBS), viral load monitoring with this system is not practical
179 adaptation of immunosuppression according to viral load monitoring.
180 e receiving WHO-recommended ART regimens and viral load monitoring.
181 itiation and annually thereafter for CD4 and viral load monitoring.
182 ited operator input to enhance the access to viral load monitoring.
183 ains will likely impact the scale-up of both viral-load monitoring and HIVDR testing.
184 rhesus macaques with regards to reduction of viral load, morbidity, or survival highlighting the chal
185 24 month risk ratios of virological failure (viral load more than 200 copies per mL) were 2.01 (1.17-
186 behave similarly and achieve an undetectable viral load much faster than DRVrtv.
187 It is known that despite high viral loads, natural hosts have a low frequency of CD4(+
188 oir size, with the evolution of intermediate viral loads observed only when the within-host dynamics
189 g both elite controllers (ie, persons with a viral load of </=40 copies/mL) and noncontrollers, antib
190 ebig stage I infection with a median initial viral load of 2.97 log10 copies per mL (IQR 2.42-3.85).
191 enrolment, the proportion who died or had a viral load of 400 copies/mL or higher at 12 months post-
192 load <50 copies per mL for >/=2 months; one viral load of 50-200 copies per mL was allowed within 12
193 ays), an HCV genotype 1, and a mean baseline viral load of 7.79 million IU/mL, were treated.
194 IV-infected veterans, time-updated HIV-1 RNA viral load of at least 500 copies/mL compared with less
195 the magnitude, function, and relation to the viral load of HIV-specific CD4(+) T cell responses in a
196 We defined viral suppression as a viral load of less than 500 copies per mL.
197 We monitored the viral load of MJNV RNA in various tissues of shrews, whi
198 notyping was done in 1589 individuals with a viral load of more than 1000 copies per mL.
199 iral rebound was defined as the first single viral load of more than 200 copies per mL or treatment i
200 69%) were defined by measurement of a single viral load of more than 200 copies per mL, and 1414 (31%
201 trols for some viruses, the utility in using viral load of URT specimens to define viral pneumonia wa
202 nd up to 43% of the genome from samples with viral loads of 10(4) and 10(3) IU/ml respectively.
203 men aged 18 years or older who had HIV-1 RNA viral loads of 500 copies per mL or greater, had receive
204 n the protease inhibitor plus NRTI group had viral loads of less than 400 copies per mL compared with
205 itor monotherapy group, 292 (78%) of 375 had viral loads of less than 400 copies per mL; p=0.003 vers
206 of 247 in the atazanavir group had HIV-1 RNA viral loads of less than 50 copies per mL (mean differen
207 he proportion of participants with HIV-1 RNA viral loads of less than 50 copies per mL at week 48 in
208 n antiretroviral therapy, and 29 (36.7%) had viral loads of more than 50 000 copies per mL.
209 IV-infected persons who achieve undetectable viral loads on antiretroviral therapy currently have nea
210 t women with confirmed EVD had similar Ebola viral loads on presentation to nonpregnant women, as mea
211 l1r1(-/-) mice, did not have increased brain viral loads or BBB disruption.
212 CI, 2.5-151.3) and higher maternal HIV log10 viral load (OR, 2.8; 95% CI, 1.3-6.3) were also signific
213 differences in neuroimaging studies, plasma viral load, or outcomes at 6 months were found.
214 reexposure prophylaxis (P = .01), low plasma viral load (P < .02), and time to kit expiration (P < .0
215 val [CI]: 0.796-1.270); disease severity and viral load (P = .994); viral load and adverse outcomes (
216 her pre-ART CD4 count (p=0.0008) and pre-ART viral load (p=0.0003) were associated with viral rebound
217 positive results were associated with lower viral loads (P < .001).
218 There is a global need for HIV viral load point-of-care (PoC) assays to monitor patient
219 and Thailand, which have already established viral load programmes.
220 h detectable and 20 with undetectable plasma viral load (pVL) (<20 copies/ml).
221 DENV infections were detected and viral load quantitated by real-time reverse transcriptio
222 Nasopharyngeal samples for viral load quantitation, typing, and genotyping, and blo
223 stic regression analyses suggested that high viral load, receipt of high-dose steroids, and myeloabla
224 At week 4, the median viral load reduction from baseline was 4.42 (IQR 3.23-5.
225 s well tolerated and resulted in substantial viral load reduction in all treated patients within 4 we
226 2 oligonucleotide, resulted in a significant viral load reduction in patients with chronic HCV infect
227 for participants with and without detectable viral load, respectively).
228 anel for HEV genotypes (code 8578/13) showed viral load results falling within the result ranges gene
229 Variability in viral load results remains a challenge across all viruse
230 The viral load results were exponentiated (with base 10) for
231 This was particularly the case for EBV viral load results.
232 in PBMC correlated directly with both plasma viral load (Rho = 0.3531; P = 0.0218) and the proviral c
233 iew we propose a new framework to accelerate viral load scale-up and ensure equitable access to this
234 ytic immune response that impacts the plasma viral load set point and the rate of progression to AIDS
235 Two of the cases with the highest viral loads showed a coincident expansion of activated E
236 Viral loads showed a high degree of interlaboratory vari
237 rimary infections have very high circulating viral loads similar to those in patients during the acut
238 l infectivity, correlates with the set point viral load (Spearman r = 0.346; P = 0.045) and that repl
239 cted NRTI activity was associated with worse viral load suppression (global p=0.0004).
240 ith HIV on antiretroviral therapy (ART) with viral load suppression will be able to continue before d
241 HIV viral-load suppression among all HIV-positive persons in
242 Changes in population-level viral-load suppression and sexual behaviors were also ex
243 ART, participant-reported male circumcision, viral-load suppression, and sexual behaviors.
244 rforms well compared to a market-leading HCV viral load test and should be considered for instances w
245 IMPLICATIONS: The Xpert HCV Viral Load test can detect active infection from a finge
246 sensitivity and specificity of the Xpert HCV Viral Load test for HCV RNA detection by venepuncture an
247 CV antibody-reactive patients, 435 completed viral load testing (82%), of whom 301 (69%) were chronic
248 Scaling up access to HIV viral load testing for individuals undergoing antiretrov
249 016, and July 27, 2016, 150 participants had viral load testing results for the three assays tested.
250 countries that have just started to scale up viral load testing, lessons can be learnt from countries
251 IV screening and CD4 counts, and in-parallel viral load testing, to promote fast and complete diagnos
252 would improve interlaboratory agreement for viral load testing; however, insufficient data are avail
253 as assessed with WHO criteria, confirmed by viral-load testing.
254 nd patients, which will be vital in ensuring viral load tests are appropriately used to improve the q
255 We optimized the interval between viral load tests as a function of patients' age, gender,
256 y severe pneumonia cases did not have higher viral load than less severe cases for most viruses.
257 ssion, as is observed, and not the very high viral loads that previous models have predicted, an effe
258 HIV-1 set-point viral load-the approximately stable value of viraemia in
259 , we show that IFNL4 genotypes determine HCV viral load through a mechanism dependent on a specific a
260 strongly with both neutralization titers and viral load titers in the nose and lungs post-viral chall
261 ld by adjuvant and inversely correlated with viral load titers.
262 ter detection, which limited the median peak viral load to 4.22 log10 copies per mL (3.27-4.83) and t
263 ntrollers (EC), with the ability to suppress viral load to undetectable levels in the absence of anti
264 ally experience viral rebound, the return of viral loads to pretreatment levels.
265 ART also suppressed viral load (to <20 copies per mL) within a median of 16
266 inst HIV-1 protect from infection and reduce viral load upon therapeutic applications.
267 ontrast to previous studies, (i) we measured viral loads using standardized assays on a sample collec
268 people with observed viral rebound, the next viral load value after rebound was 50 copies per mL or l
269 imited to 175 men with detectable HIV plasma viral load (VL > 400 copies/mL; n = 808 visits).
270 Triangulation of viral load (VL) and HIVDR testing data could be pursued
271 that the median time to undetectable plasma viral load (VL) can be reduced from approximately 5 d to
272 We measured viral load (VL) in 124 fluid samples (oral, urine, vagin
273 Viral load (VL) monitoring for patients receiving antire
274 Although WHO recommends viral load (VL) monitoring for those on antiretroviral t
275 rs associated with higher CD4 cell count and viral load (VL) suppression<400 c/mL among patients on a
276 ens through 12 months postpartum for batched viral load (VL) testing separate from routine care.
277 We compared the rectal HCV viral load (VL) with paired blood HCV VL.
278 bout the association of age, CD4 cell count, viral load (VL), and antiretroviral (ARV) drug use with
279 ase-related factors, including CD4 count and viral load (VL), are unknown.
280 hedding among women with undetectable plasma viral load (VL).
281 itis B virus and hepatitis delta virus (HDV) viral loads (VL) during tenofovir-containing antiretrovi
282 ither cerebrospinal fluid (CSF) discordance (viral load [VL] in CSF 0.5 log10 copies HIV-1 RNA greate
283 asma human immunodeficiency virus (HIV) RNA (viral load [VL]) testing; however, its availability is v
284 ive partner was viraemic (and in 69 [14.0%], viral load was >100 000 copies per mL).
285 tive partner was viraemic (and in 129 [15%], viral load was >100 000 copies per mL).
286 three timepoints (months 5, 10, and 15), log viral load was 1.26 times higher (95% CI 1.04-1.52) in t
287 The elevated viral load was associated with the release of high mobil
288 The mean viral load was higher in cases than controls for 7 virus
289 CMV shedding rate and viral load were higher in children with primary infectio
290 HHV-6 shedding rate and viral load were similar between children with primary or
291 gut at 10-12 days post-infection when blood viral loads were low.
292 No detectable viral loads were observed in this study.
293 Age <5 years, bleeding, and high viral loads were poor prognostic indicators of children
294 t infection as well as in reducing the nasal viral load when administered via the subcutaneous route.
295 must quantify the heritability of set-point viral load, which is the fraction of variation in this p
296 c diversity explains 29% of the variation in viral load while host factors explain 8.4%.
297 The association of viral load with case status was evaluated using logistic
298 be useful for guiding the implementation of viral load with the aim of achieving the new global HIV
299 ospectively and retrospectively to track the viral load within the patient blood, urine, CSF, and kid
300 he key blood sample had high cell-associated viral loads without a marked CD8 lymphocytosis or NK cel
WebLSDに未収録の専門用語（用法）は "新規対訳" から投稿できます。